Welcome to our dedicated page for SCIENTIFIC INDUSTRIES SEC filings (Ticker: SCND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scientific Industries, Inc. filings document the company’s life science tool operations, governance matters and material events tied to its continuing DOTS bioprocessing, VIVID pill counter and Torbal businesses. Recent 8-K and amended 8-K filings cover the completed sale of the Genie Division assets, related pro forma financial information, transition and supply arrangements, and a change in the company’s independent registered public accounting firm.
Proxy filings describe annual meeting voting matters and shareholder governance procedures. Periodic-report notices and Form 10-Q-related disclosures address reporting timing, financial-statement preparation and the company’s formal public-company reporting obligations.
Scientific Industries Inc (SCND) reported that chairman and director John Moore acquired 20,000 shares of common stock on 12/05/2025 at $0.6048 per share. Following this purchase, he directly owns 645,171 shares, giving him a larger personal stake in the company.
Scientific Industries, Inc. has amended a prior current report to add pro forma financial information related to the sale of substantially all assets of its Genie Division of benchtop laboratory equipment to Troemner, LLC. Under the Asset Purchase Agreement dated August 7, 2025, the Genie line’s products, fixed assets, inventory, and intellectual property were transferred.
The purchase price is $9,600,000, subject to working capital adjustments, plus an earn-out of up to $1,500,000, including $1,140,000 tied to the company providing supply and transition services such as product supply, training, and know-how transfer for at least six months and up to twelve months. Scientific Industries will continue to operate its Torbal Division of benchtop laboratory equipment from Bohemia, New York, and has filed unaudited pro forma balance sheet and income statement information as Exhibit 99.1.
Scientific Industries, Inc. (SCND) reported a sharp turnaround in Q3 2025 driven by the sale of its Genie Division. Net revenues from continuing operations for the quarter rose to $1,404,000 from $1,334,400, mainly from higher Torbal VIVID pill counter sales, while Bioprocessing revenues declined. Despite this, continuing operations still generated a quarterly operating loss of $1,522,300.
The August 7, 2025 sale of the Genie Division to Troemner, LLC produced a gain of $5,263,400 on consideration of $9,600,000 (before adjustments), resulting in Q3 net income of $3,994,400 versus a net loss of $1,180,100 a year earlier. For the nine months, the company posted net income of $692,200 compared with a $4,515,400 loss in 2024, even as it recorded a $5,434,700 loss from continuing operations and used $4,390,700 of cash in operating activities. Cash and cash equivalents were $1,162,600 and investment securities $7,131,100 as of September 30, 2025, and shareholders’ equity increased to $12,461,700.
Scientific Industries, Inc. filed a Form 12b-25 (NT 10-Q) notifying of a late filing for its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company states it is unable to complete its financial statements "without unreasonable effort or expense."
This notice alerts investors that the quarterly report will be delayed while the company finalizes its financial statements. The filing identifies Helena R. Santos, President and Chief Executive Officer, as the contact signatory.
Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach filed Amendment No. 4 to Schedule 13D regarding Scientific Industries, Inc. They report beneficial ownership of 2,715,026 shares, equal to 21.19% of the outstanding common stock.
The filing states sole voting power and sole dispositive power over 2,715,026 shares, with no shared voting or dispositive power. The ownership figure includes shares issuable upon the exercise of warrants. The date of event triggering the amendment is 09/30/2025. Source of funds is listed as AF, and reporting person types are identified as IA (Bleichroeder LP), HC (Bleichroeder Holdings LLC), and IN (Andrew Gundlach).
Scientific Industries, Inc. (SCND) received an Amendment No. 4 to Schedule 13G from North Run entities and affiliates reporting beneficial ownership of 1,189,632 shares of common stock, equal to 9.99% of the class.
The reported amount includes 835,000 common shares and 354,632 warrants that are exercisable within 60 days. As of September 30, 2025, the reporting group held an aggregate of 920,000 warrants, but only 354,632 are currently exercisable due to beneficial ownership limitations. The percentage was calculated using 11,553,599 shares outstanding as of August 19, 2025.
The reporting persons have shared voting and dispositive power over the 1,189,632 shares and no sole power. They certified the securities were not acquired for the purpose of changing or influencing control.
Scientific Industries, Inc. (SCND) reporting person John J. Nicols, a director, exercised 15,000 warrants on 08/20/2025 at an exercise price of $1.00 per share. The exercise converted the warrants into 15,000 shares of common stock, increasing the reporting person's total beneficial ownership to 90,778 shares. The filing indicates the transaction was a direct acquisition and does not disclose any concurrent sale of the shares. The signed Form 4 was dated 10/06/2025.
John A. Moore, Chairman and Director of Scientific Industries Inc. (SCND), reported a personal purchase of 5,800 shares of the company's common stock on 09/17/2025 at a price of $0.70 per share. After the transaction he beneficially owned 467,089 shares. The Form 4 was signed by John Moore on 09/18/2025 and was filed as a single reporting person disclosure.
Director John A. Moore purchased 9,599 shares of Scientific Industries Inc. (SCND) on 09/16/2025 at $0.64 per share. After the transaction he beneficially owns 461,289 shares. The Form 4 indicates the filing was signed on 09/18/2025 and identifies Moore as a company director. No derivative transactions or other securities changes are reported.